ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Entry into a Material Definitive Agreement


ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Entry into a Material Definitive Agreement
Item 9.01. Entry Into A Material Definitive Agreement.

On April3, 2018, Aralez Pharmaceuticals US Inc. (“Aralez US”), a Delaware company and a wholly-owned, indirect subsidiary of Aralez Pharmaceuticals Inc., a company formed under the laws of the Province of British Columbia, Canada, entered into a Modification of Contract (the “Contract Modification”) to which the United States of America (the “Government”) exercised its second renewal option under that certain VA National Contract, effective April29, 2016, between Aralez US (by novation from AstraZeneca Pharmaceuticals LP) and the Government (the “Agreement”), extending the term of the Agreement by one year to April28, 2019 on the same pricing terms as have been in effect during the April29, 2017 through April28, 2018 annual term except for a price decrease to the 200mg SKUs only (which are currently the smallest selling SKUs). Under the Agreement, Aralez US provides products containing metoprolol succinate (sold under the brand name Toprol-XL®) as the active pharmaceutical ingredient at fixed prices to the U.S. Department of Veterans Affairs and certain other United States federal government agencies. The Contract Modification is filed as Exhibit10.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d)List of Exhibits




Modification of Contract, executed on April3, 2018, between the United States of America and Aralez Pharmaceuticals US Inc.

Aralez Pharmaceuticals Inc. Exhibit
EX-10.1 2 a18-9638_1ex10d1.htm EX-10.1 Exhibit 10.1 IOFP GES 1 CONTRACT 10 COOE 18PANO AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT IPA OPAL I National Acquisition Center lst Avenue,…
To view the full exhibit click here


Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).